Humacyte (HUMA) Change in Receivables (2020 - 2026)
Humacyte (HUMA) posted quarterly Change in Receivables of -$7000.0 for Q1 2026, down 102.27% year-over-year from $308000.0 in Q1 2025, and up 98.9% quarter-over-quarter from -$637000.0 in Q4 2025.
Humacyte (HUMA) Change in Receivables (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Change in Receivables for 6 consecutive years, with -$7000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 102.27% year-over-year to -$7000.0; the TTM figure through Mar 2026 stood at -$54000.0 (down 117.53% YoY), while the FY2025 annual figure was $261000.0, changed N/A from the prior year.
- Change in Receivables grew to -$7000.0 in Q1 2026 per HUMA's latest filing, from -$637000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.1 million in Q2 2022 and bottomed at -$1.3 million in Q3 2022.
- Historically, Change in Receivables has averaged $8666.7 across 4 years, with a median of -$7000.0 in 2026.
- On a YoY basis, Change in Receivables climbed as much as 100.0% in 2022 and fell as far as 182.85% in 2022.
- Humacyte's Change in Receivables stood at -$1.3 million in 2022, then surged by 97.56% to -$31000.0 in 2023, then plunged by 1954.84% to -$637000.0 in 2025, then surged by 98.9% to -$7000.0 in 2026.
- Business Quant data shows HUMA's Change in Receivables at -$7000.0 in Q1 2026, -$637000.0 in Q4 2025, and $684000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -104,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104,000.00 |
| Jun 30, 2026 | -104,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Dec 31, 2025 | -637,000.00 |
| Dec 31, 2025 | -637,000.00 |
| Sep 30, 2025 | 684,000.00 |
| Sep 30, 2025 | 684,000.00 |
| Jun 30, 2025 | -94,000.00 |
| Jun 30, 2025 | -94,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Sep 30, 2022 | -1.27 Mn |
| Sep 30, 2022 | -1.27 Mn |
| Jun 30, 2022 | 1.07 Mn |
| Jun 30, 2022 | 1.07 Mn |
| Mar 31, 2022 | 57,000.00 |
| Mar 31, 2022 | 57,000.00 |